44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Clinical Psychiatry and Neuroscience

Sign up for email alert when new content gets added: Sign up

David K Ho M.D1*#, Fabrizio Pavone M.D.2#, Andrea Fagiolini M.D.3# and Stefano Gelati M.D.4#
 
1 Essex Partnership University NHS Foundation Trust,

Kemble Way, Wickford

, UK, Email: David.ho@nhs.net
2 Azienda Socio-Sanitaria Territoriale (ASST) di Pavia, Italy, Email: fabrizio_pavone@asst-pavia.it
3 Dipartimento di Medicina Molecolare e Dello Sviloppo, Universita di Siena, Italy, Email: andrea.fagiolini@unisi.it
4 Essex Partnership University NHS Foundation Trust,

Kemble Way, Wickford

, UK, Email: stefano.gelati@sept.nhs.uk
#Equally contribution
 
*Correspondence: David K Ho M.D, Essex Partnership University NHS Foundation Trust,

Kemble Way, Wickford, Essex, SS11 7FE

, UK, Tel: 01268 568092 (Extn. 4092), Email: David.ho@nhs.net

Received: 01-May-2020 Accepted Date: May 25, 2020; Published: 03-Jul-2020

Citation: Pavone F, Fagiolini A, Ho DK, et al. Psychopharmacological treatment of Delirium in patients who are COVID-19+. JCPN 2020;3(1):1-5.

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

Abstract

The scale and speed of the COVID-19 pandemic has been devastating both to patients and healthcare systems globally. This article provides concise and accessible information regarding well known pharmacological treatments for delirium in patients who are COVID+. It draws from the experience from clinicians in Italy, which was the initial epicentre of the outbreak in Europe.

The agents reviewed here provide effects, side effects and interactions with other medications which are commonly used to treat patients, including antiviral agents. In conclusion, clinicians should recognise and treat delirium promptly in COVID+ patients given its potential to alleviate distress in patients, and allow for healthcare systems not to be unduly distracted by patients who present with delirium and agitation.

 
Google Scholar citation report
Citations : 60

Journal of Clinical Psychiatry and Neuroscience received 60 citations as per Google Scholar report

pulsus-health-tech
Top